Madrigal Pharmaceuticals
Generated by Meeveem AI
"Delivering the first FDA-approved treatment for MASH, a serious and progressive liver disease"
West Conshohocken, PA
•1000+ Employees
•Pharmaceuticals
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals develops novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease affecting millions. MASH occurs when liver fat becomes toxic, damaging cells and causing inflammation and scarring that progresses to cirrhosis, liver failure, cancer, and death. Madrigal's research delivered the first FDA-approved MASH treatment. The company focuses on halting or reversing liver fibrosis before devastating complications occur. With 1,000 professionals across the United States and Europe, Madrigal addresses critical unmet medical need through rigorous clinical development and patient-centred innovation, transforming scientific breakthroughs into treatments that restore liver health.
1000
Team Members
2011
Founded
Pharmaceuticals
Sector
Hybrid
Work Environment
Our Vision
A world where MASH patients avoid cirrhosis, liver failure, transplants, and premature death through early intervention that halts disease progression and restores liver health before devastating complications occur.
Our Mission
At Madrigal, our mission is to lead the fight against MASH by delivering novel therapeutics that halt or reverse liver scarring before patients experience devastating complications.